Mesa Laboratories presents a mixed fundamental picture. The company has made significant progress in deleveraging, reducing total debt by over 55% from $224.7M to $101.4M and improving its current ratio from a concerning 0.63 to a healthy 2.07. However, this f...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | $2.68+1.9% vs $2.63 | $60M-1.2% vs $61M |
Q2 2026 May 27, 2026 | $2.76+32.1% vs $2.09 | $64M-2.3% vs $65M |
Q1 2026 Feb 3, 2026 | $3.07+119.3% vs $1.40 | $65M+3.0% vs $63M |
Q4 2025 Nov 6, 2025 | $1.76-23.5% vs $2.30 | $61M+0.0% vs $61M |
On September 02, 2026, Mesa Laboratories Inc (MLAB) shares rose 4.1% to $130.65, reflecting a significant increase within a volatile 52-week range of $58.83 to
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) and ImmunoPrecise Antibodies (OTCMKTS:IPATF - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Earnings and Valuation This table compares Mesa Laboratories
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
Benchmark MLAB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mesa Laboratories, Inc. (MLAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $134.63 | $753.37M | 111.26 | 3.38% | 2.69% | 3.88% | 0.47% | |
| $13.98 | $3.04B | -349.50 | -2.71% | -0.91% | -0.37% | — | |
| $418.88 | $10.64B | -144.44 | 8.92% | -0.31% | -0.32% | — | |
| $144.17 | $5.13B | 98.07 | 3.3% | 6% | 4.9% | — | |
| $186.70 | $10.54B | 217.09 | 16.36% | 5.29% | 1.98% | — | |
| $59.30 | $13.82B | 33.89 | -2.61% | -2.77% | -1.87% | — |
Mesa Laboratories, Inc. (MLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mesa Laboratories, Inc. (MLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jul 30, 2026·SEC
Jun 15, 2026·SEC
Get notified when MLAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mesa Laboratories, Inc. (MLAB) stock FAQ — growth, dividends, profitability & financials explained
Mesa Laboratories, Inc. (MLAB) reported $249.7M in revenue for fiscal year 2026. This represents a 3102% increase from $7.8M in 1997.
Mesa Laboratories, Inc. (MLAB) grew revenue by 3.4% over the past year. Growth has been modest.
Yes, Mesa Laboratories, Inc. (MLAB) is profitable, generating $4.8M in net income for fiscal year 2026 (2.7% net margin).
Yes, Mesa Laboratories, Inc. (MLAB) pays a dividend with a yield of 0.47%. This makes it attractive for income-focused investors.
Mesa Laboratories, Inc. (MLAB) has a return on equity (ROE) of 3.9%. This is below average, suggesting room for improvement.
Mesa Laboratories, Inc. (MLAB) generated $56.1M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
